PMID- 28461752
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 13
DP  - 2017
TI  - The effectiveness and safety of amisulpride in Chinese patients with 
      schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of 
      the ESCAPE study.
PG  - 1163-1173
LID - 10.2147/NDT.S132363 [doi]
AB  - INTRODUCTION: Second-generation antipsychotics show significant interpatient 
      variability in treatment response and side-effect profiles, and the majority of 
      patients with schizophrenia require multiple treatment changes. This subgroup 
      analysis of the ESCAPE study evaluated the efficacy and safety of amisulpride in 
      Chinese patients with schizophrenia who switched from risperidone or olanzapine. 
      METHODS: ESCAPE was a prospective, open-label, multicenter, single-arm Phase IV 
      study in which Chinese patients with an ICD-10 diagnosis of schizophrenia 
      received amisulpride for 8 weeks. This analysis included 109 patients who 
      switched to amisulpride from risperidone (n=68) or olanzapine (n=41) and 59 
      treatment-naive patients for reference. The primary effectiveness outcome was a 
      >/=50% decrease in Positive and Negative Syndrome Scale (PANSS) Total score from 
      Baseline to Week 8. The study was registered at ClinicalTrials.gov (NCT01795183). 
      RESULTS: Of the patients who switched from risperidone and olanzapine, 77.9% and 
      56.1% achieved >/=50% reduction in PANSS Total score from Baseline to Week 8 and 
      57.4% and 46.3% achieved >/=20% reduction in PANSS score from Baseline to Week 2, 
      respectively; these end points were achieved by 66.1% and 61.0% of 
      treatment-naive patients, respectively. No unexpected adverse events (AEs) were 
      reported. Of the most common AEs, extrapyramidal side effects occurred in 32.4% 
      and 14.6%, blood prolactin increase in 32.4% and 39.0%, and >/=7% increase in body 
      weight in 4.4% and 12% of patients switching from risperidone and olanzapine, 
      respectively. CONCLUSION: The results of this subgroup analysis suggest that 
      switching to amisulpride from risperidone and olanzapine is effective and 
      generally well tolerated in Chinese patients with schizophrenia.
FAU - Liang, Ying
AU  - Liang Y
AD  - Peking University Sixth Hospital, Peking University Institute of Mental Health, 
      Key Laboratory of Mental Health, Ministry of Health (Peking University), National 
      Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), 
      Beijing, People's Republic of China.
FAU - Yu, Xin
AU  - Yu X
AD  - Peking University Sixth Hospital, Peking University Institute of Mental Health, 
      Key Laboratory of Mental Health, Ministry of Health (Peking University), National 
      Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), 
      Beijing, People's Republic of China.
LA  - eng
SI  - ClinicalTrials.gov/NCT01795183
PT  - Journal Article
DEP - 20170421
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC5407443
OTO - NOTNLM
OT  - China
OT  - amisulpride
OT  - olanzapine
OT  - risperidone
OT  - schizophrenia
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/05/04 06:00
MHDA- 2017/05/04 06:01
PMCR- 2017/04/21
CRDT- 2017/05/03 06:00
PHST- 2017/05/03 06:00 [entrez]
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2017/05/04 06:01 [medline]
PHST- 2017/04/21 00:00 [pmc-release]
AID - ndt-13-1163 [pii]
AID - 10.2147/NDT.S132363 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2017 Apr 21;13:1163-1173. doi: 10.2147/NDT.S132363. 
      eCollection 2017.